Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations
Rianne A. Weersink, David M. Burger, Kelly L. Hayward, et al.
Expert Opinion on Drug Metabolism & Toxicology (2019) Vol. 16, Iss. 1, pp. 45-57
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

The pharmacokinetics of antibiotics in cystic fibrosis
Anne M. Akkerman‐Nijland, Onno W. Akkerman, Floris Grasmeijer, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 17, Iss. 1, pp. 53-68
Open Access | Times Cited: 56
Remimazolam Tosilate Sedation with Adjuvant Sufentanil in Chinese Patients with Liver Cirrhosis Undergoing Gastroscopy: A Randomized Controlled Study
Yinghao Cao, Ping Chi, Chen Zhou, et al.
Medical Science Monitor (2022) Vol. 28
Open Access | Times Cited: 26
Recommendations for the safe use of direct oral anticoagulants in patients with cirrhosis based on a systematic review of pharmacokinetic, pharmacodynamic and safety data
Maaike M. E. Diesveld, Daniëlle W. M. Jacobs- Pijnenburg, Rianne A. Weersink, et al.
European Journal of Clinical Pharmacology (2024) Vol. 80, Iss. 6, pp. 797-812
Closed Access | Times Cited: 5
Design and conduct considerations for studies in patients with hepatic impairment
Paulien Ravenstijn, Manoranjenni Chetty, Pooja Manchandani, et al.
Clinical and Translational Science (2022) Vol. 16, Iss. 1, pp. 50-61
Open Access | Times Cited: 20
Antibiotics in decompensated liver disease - who, when and for how long?
Frederic Haedge, Tony Bruns
Expert Review of Gastroenterology & Hepatology (2025)
Closed Access
Opportunities and Challenges of Hepatic Impairment Physiologically Based Pharmacokinetic Modeling in Drug Development—An IQ Perspective
Hisham Qosa, Islam R. Younis, Vaishali Sahasrabudhe, et al.
Clinical Pharmacology & Therapeutics (2025)
Closed Access
The Safety and Efficacy of Anticancer Therapy in Breast Cancer Patients with Liver Cirrhosis
Zhanyi Li, Teng Yuan, Chen-Meng Long, et al.
Cancer Management and Research (2025) Vol. Volume 17, pp. 639-650
Open Access
Drug Disposition in Hepatic Insufficiency
Fried A. Abilba, Jacob Apibilla Ayembilla, Raphael N. Alolga
(2025), pp. 327-348
Closed Access
Appropriate and Potentially Inappropriate Medication Use in Decompensated Cirrhosis
Mary Thomson, Anna S. Lok, Elliot B. Tapper
Hepatology (2020) Vol. 73, Iss. 6, pp. 2429-2440
Open Access | Times Cited: 29
Proteomic Quantification of Changes in Abundance of Drug-Metabolizing Enzymes and Drug Transporters in Human Liver Cirrhosis: Different Methods, Similar Outcomes
Eman El‐Khateeb, Zubida M. Al‐Majdoub, Amin Rostami‐Hodjegan, et al.
Drug Metabolism and Disposition (2021) Vol. 49, Iss. 8, pp. 610-618
Open Access | Times Cited: 24
Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders
Cristiana Bianco, Elena Coluccio, Daniele Prati, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 3, pp. 423-423
Open Access | Times Cited: 18
Simultaneously Predicting the Pharmacokinetics of CES1-Metabolized Drugs and Their Metabolites Using Physiologically Based Pharmacokinetic Model in Cirrhosis Subjects
Xin Luo, Zexin Zhang, Ruijing Mu, et al.
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 234-234
Open Access | Times Cited: 2
Improving Medication‐Related Outcomes in Chronic Liver Disease
Kelly L. Hayward, Rianne A. Weersink
Hepatology Communications (2020) Vol. 4, Iss. 11, pp. 1562-1577
Open Access | Times Cited: 17
Effects of chronic cirrhosis induced by intraperitoneal thioacetamide injection on the protein content and Michaelis–Menten kinetics of cytochrome P450 enzymes in the rat liver microsomes
Devaraj V. Chandrashekar, Barent DuBois, Mamunur Rashid, et al.
Basic & Clinical Pharmacology & Toxicology (2022) Vol. 132, Iss. 2, pp. 197-210
Open Access | Times Cited: 9
Application of physiologically based pharmacokinetic modeling to understand real‐world outcomes in patients receiving imatinib for chronic myeloid leukemia
Josephine Adattini, Jeffry Adiwidjaja, Annette S. Gross, et al.
Pharmacology Research & Perspectives (2023) Vol. 11, Iss. 4
Open Access | Times Cited: 4
Managing medicines in alcohol-associated liver disease: a practical review
Amy Johnson, Kelly L. Hayward
Australian Prescriber (2021) Vol. 44, Iss. 3, pp. 96-106
Open Access | Times Cited: 9
Inconsistencies and Ambiguities in Liver-Disease-Related Contraindications—A Systematic Analysis of SmPCs/PI of Major Drug Markets
Laura Weisbach, Anna K. Schuster, Michael Hartmann, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 7, pp. 1933-1933
Open Access | Times Cited: 5
The 50% and 95% effective doses of remimazolam tosilate with adjuvant sufentanil for sedation in patients with liver cirrhosis undergoing oesophagogastric varices screening endoscopy
Ying Cao, Ping Chi, Chen Zhou, et al.
Journal of Clinical Pharmacy and Therapeutics (2022) Vol. 47, Iss. 12, pp. 2068-2073
Closed Access | Times Cited: 5
Risk factors for and preventability of drug‐related hospital revisits in older patients: A post‐hoc analysis of a randomized clinical trial
Thomas Kempen, Anton Hedman, Nermin Hadziosmanovic, et al.
British Journal of Clinical Pharmacology (2022) Vol. 89, Iss. 5, pp. 1575-1587
Open Access | Times Cited: 5
Dose Recommendations for Common Drugs in Patients with Liver Cirrhosis: A Systematic Literature Review
Katharina Karsten Dafonte, Lisa Weber, Florian Chmielewski, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 7, pp. 475-502
Open Access | Times Cited: 2
Hepatic Impairment as a Risk Factor for Drug Safety: Suitability and Comparison of Four Liver Scores as Screening Tools
Kathrin Golla, Andreas Benesic, Hanna Mannell, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 21, pp. 6814-6814
Open Access | Times Cited: 2
Hepatic Insufficiency
Ivana Mikolašević, Tajana Filipec Kanižaj, Viktor Domislović, et al.
Clinical gastroenterology (2024), pp. 367-382
Closed Access
Farmacocinética de las Benzodiacepinas en Pacientes con Falla Hepática en UCI
Martín Martínez Peredo, Andrea Gissette Soler Sierra, Valentina Rivas García, et al.
Ciencia Latina Revista Científica Multidisciplinar (2024) Vol. 8, Iss. 2, pp. 338-351
Open Access
Prevalence of human herpesvirus in plasma and saliva of cirrhotic patients: A pilot study
Gabriella Bueno Marinho, Juliana Bertoldi Franco, Jefferson da Rocha Tenório, et al.
Special Care in Dentistry (2024) Vol. 44, Iss. 5, pp. 1476-1484
Closed Access
A Phase 1, Single‐Dose Study to Evaluate the Pharmacokinetics and Safety of Bepirovirsen in Adults with Hepatic Impairment and Healthy Participants (B‐Assured)
Nadia Noormohamed, Tamara Lukić, Thomas Marbury, et al.
Clinical Pharmacology in Drug Development (2024)
Open Access
Page 1 - Next Page

Scroll to top